These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3878975)

  • 1. Fluoxetine in the treatment of obsessive compulsive disorder.
    Fontaine R; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):605-8. PubMed ID: 3878975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.
    Fontaine R; Chouinard G
    J Clin Psychopharmacol; 1986 Apr; 6(2):98-101. PubMed ID: 3517083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine treatment of obsessive-compulsive disorder.
    Turner SM; Jacob RG; Beidel DC; Himmelhoch J
    J Clin Psychopharmacol; 1985 Aug; 5(4):207-12. PubMed ID: 3894437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
    Liebowitz MR; Hollander E; Schneier F; Campeas R; Hatterer J; Papp L; Fairbanks J; Sandberg D; Davies S; Stein M
    J Clin Psychopharmacol; 1989 Dec; 9(6):423-7. PubMed ID: 2687337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiobsessive effect of fluoxetine.
    Fontaine R; Chouinard G
    Am J Psychiatry; 1985 Aug; 142(8):989. PubMed ID: 3875293
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A; Rosenthal J; Nezu A; Winston A
    Mt Sinai J Med; 1990 Nov; 57(6):348-52. PubMed ID: 2079952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience.
    Eapen V; Trimble MR; Robertson MM
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):737-43. PubMed ID: 8843495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder.
    Costa DLDC; Barbosa VS; Requena G; Shavitt RG; Pereira CAB; Diniz JB
    J Psychopharmacol; 2017 Oct; 31(10):1312-1322. PubMed ID: 28441896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients.
    Levine R; Hoffman JS; Knepple ED; Kenin M
    J Clin Psychopharmacol; 1989 Aug; 9(4):281-3. PubMed ID: 2504781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine in the treatment of obsessive compulsive disorder.
    Montgomery SA; Manceaux A
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():5-9. PubMed ID: 1355499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obsessive disorder with self-mutilation: a subgroup responsive to pharmacotherapy.
    Primeau F; Fontaine R
    Can J Psychiatry; 1987 Nov; 32(8):699-701. PubMed ID: 3500773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.
    Greenberg BD; Benjamin J; Martin JD; Keuler D; Huang SJ; Altemus M; Murphy DL
    Psychopharmacology (Berl); 1998 Dec; 140(4):434-44. PubMed ID: 9888619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation.
    Bodfish JW; Madison JT
    Am J Ment Retard; 1993 Nov; 98(3):360-7. PubMed ID: 8292312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
    Jenike MA; Baer L; Buttolph L
    J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.